3 No-Brainer Growth Stocks to Buy in October
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Morningstar18h
Obesity Drug Market: The Next Wave of GLP-1 Competition
New drugs from public and private companies are expected to saturate the obesity drug market. Novo Nordisk and Eli Lilly are currently dominating the weight loss drug market, but biopharmaceutical ...
thedailyupside9h
Weight-Loss Drugs Might Not Tank Medicare After All
New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.
GLP-1 Stocks Aren't the Only Way to Benefit From the Weight Loss Drugs Boom
The future of the weight loss market might not revolve around GLP-1 drugs.
Eli Lilly CEO told UK health secretary its Alzheimer's treatment could "prevent" disease: FT
Chief Executive David Ricks told then-UK Health Secretary Victoria Atkins last December that the company’s new Alzheimer’s ...